Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Equity Average (2021 - 2025)

Prime Medicine's Equity Average history spans 5 years, with the latest figure at $141.3 million for Q4 2025.

  • For Q4 2025, Equity Average fell 17.5% year-over-year to $141.3 million; the TTM value through Dec 2025 reached $141.3 million, down 17.5%, while the annual FY2025 figure was $137.0 million, 4.26% down from the prior year.
  • Equity Average reached $141.3 million in Q4 2025 per PRME's latest filing, up from $111.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $297.5 million in Q1 2023 to a low of -$209.1 million in Q3 2022.
  • Average Equity Average over 5 years is $91.0 million, with a median of $141.3 million recorded in 2025.
  • Peak YoY movement for Equity Average: skyrocketed 284.13% in 2023, then plummeted 61.9% in 2025.
  • A 5-year view of Equity Average shows it stood at -$125.3 million in 2021, then soared by 137.17% to $46.6 million in 2022, then surged by 250.99% to $163.5 million in 2023, then grew by 4.78% to $171.3 million in 2024, then decreased by 17.5% to $141.3 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Equity Average are $141.3 million (Q4 2025), $111.3 million (Q3 2025), and $83.9 million (Q2 2025).